Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.12%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +35.00%
#5 RedStone RedStone +28.08%
#6 Humanity Humanity +25.92%
#7 Codatta Codatta +22.12%
#8 Walrus Walrus +20.05%
#9 Enso Enso +18.97%
#10 Tutorial Tutorial +17.31%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
Classifica tra le azioni #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Prezzo delle azioni
$5.34
Ultima sincronizzazione: 2026-08-14
Capitalizzazione di mercato
$2.59M
Variazione (1 giorno)
-11.00%
Variazione (1 anno)
313.95%
Paese
US
Scambia Jupiter Neurosciences, Inc. (JUNS)

Categoria

Healthcare
Rapporto P/S per Jupiter Neurosciences, Inc. (JUNS)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Jupiter Neurosciences, Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Jupiter Neurosciences, Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE